7Gonzalez-Alvaro I, Ortiz AM, Pominguez-Jimenez C, et al, In- hibition of tumour necrosis factor and IL-17 production by le- flunomide involves the JAK/STAT pathway [ J]. Ann Rheum Dis ,2009,68 (10) : 1644-1650.
9Henes, JC, Fritz J, Koch S, et al. Rituximab for treatment-re- sistant extensive Wegener's granulomatosis-additive effects of a maintenance treatment with leflunomide [ J ]. Clin Rheuma- tol,2007,26(10) :1711-1715.
10Metzler C, Fink C, Lamprecht P, et al. Maintenance of remis- sion leflunomide with Wegener' s granulomatosis [ J ]. Rheu- matology, 2004,43 ( 3 ) : 315-320.
9Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary Vaculitides[ J ]. Eur Respir J, 1997,10 : 2738 -2743.
10Jenneue JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rhrum, 1994,37(2):187-192.
7Fishbein G A, Fishbein M C.Lung vasculitis and alveolar hemorrhage: pathology [J]. Semin Respir Crit Care Med, 2011,32(3) :254-263.
8Ding Y L, Zhu H, Yao W Z, et al. Clinical analysis of diffusive interstitial lung diseases with positive ANCA [J]. Beijing Da Xue Xue Bao, 2011,43(2) :222-227.
9Chen M, Yu F, Zhang Y, et al. ANCA-associated vasculitis in older patients[J]. Medicine (Baltimore), 2008,87 (4): 203-209.
10Pesci A, Manganelli P. Respiratory system involvement in AASV clinical, pathological, radiological and therapeutic considerations [J]. Drugs R D, 2007,8( 1 ) :25-42.
